Drugs / GSK256073A
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00608699 | Dec 2007 → Apr 2008 | hyperlipidemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00551694 | Oct → Dec 2007 | hyperlipidemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00488449 | Jun → Nov 2007 | hyperlipidemia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK256073A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00551694 ↗ |
| Route | Oral | “Single and Repeat Oral Doses of GSK256073A” NCT00488449 ↗ |